Nurix
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for cancer and inflammatory diseases. Its pipeline includes BTK degraders, CBL-B inhibitors, and a range of preclinical programs such as DACs and novel degraders. Nurix also collaborates with Gilead, Sanofi, and Pfizer on IRAK4, STAT6, and other targets, retaining select U.S. co-development and profit-sharing rights. The company is advancing first- and best-in-class therapies to address significant unmet medical needs.
